{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:13:11Z","timestamp":1789427591780,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lanepe.2026.101630","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:44:00Z","timestamp":1771656240000},"page":"101630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Background incidence rates and observed-to-expected ratios of adverse events of special interest after covid-19 mRNA vaccination during pregnancy in France: a nationwide population-based study"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-4321","authenticated-orcid":false,"given":"Sylvie","family":"Escolano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2168-1477","authenticated-orcid":false,"given":"Elise","family":"Quentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Demailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isma\u00efl","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tubert-Bitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101630_bib1","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2589-7500(21)00250-8","article-title":"The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study","volume":"4","author":"Piekos","year":"2022","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.lanepe.2026.101630_bib2","article-title":"COVID-19 diagnosis, vaccination during pregnancy, and adverse pregnancy outcomes of 865,654 women in England and Wales: a population-based cohort study","volume":"45","author":"Raffetti","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101630_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127223","article-title":"Covid-19 vaccination during pregnancy in France: a descriptive study of uptake using the National Healthcare data System","volume":"58","author":"Quentin","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101630_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127070","article-title":"COVID-19 vaccination rates among pregnant women in France: a nationwide cohort study","volume":"53","author":"Bernard","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101630_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ebiom.2016.08.042","article-title":"The state of vaccine confidence 2016: global Insights through a 67-Country Survey","volume":"12","author":"Larson","year":"2016","journal-title":"eBioMedicine"},{"key":"10.1016\/j.lanepe.2026.101630_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41541-024-00913-0","article-title":"A scoping review of global COVID-19 vaccine hesitancy among pregnant persons","volume":"9","author":"Casubhoy","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.lanepe.2026.101630_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jama.2023.26945","article-title":"Neonatal outcomes after COVID-19 vaccination in pregnancy","volume":"331","author":"Norman","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2026.101630_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079364","article-title":"Covid-19 infection and vaccination during first trimester and risk of congenital anomalies: Nordic registry based study","volume":"386","author":"Magnus","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2026.101630_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000632","article-title":"Pregnancy, fetal, and neonatal outcomes after a first booster dose of covid-19 vaccine during pregnancy in Ontario, Canada: population based, retrospective cohort study","volume":"2","author":"Fell","year":"2023","journal-title":"BMJ Med"},{"key":"10.1016\/j.lanepe.2026.101630_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071416","article-title":"Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study","volume":"378","author":"Fell","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2026.101630_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101932","article-title":"Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study","volume":"58","author":"Voss","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.lanepe.2026.101630_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bpobgyn.2008.06.005","article-title":"Physiological changes of pregnancy and monitoring","volume":"22","author":"Carlin","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.lanepe.2026.101630_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837632","article-title":"Current approaches to vaccine safety using observational data: a rationale for the EUMAEUS (evaluating use of methods for adverse events under surveillance-for vaccines) study design","volume":"13","author":"Lai","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanepe.2026.101630_bib14","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1016\/j.vaccine.2023.08.079","article-title":"Background rates of adverse events of special interest for COVID-19 vaccines: a multinational Global Vaccine Data Network (GVDN) analysis","volume":"41","author":"Phillips","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101630_bib15","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101630_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2021.21699","article-title":"Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older","volume":"327","author":"Jabagi","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2026.101630_bib17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMc2302134","article-title":"Stroke, myocardial infarction, and pulmonary embolism after bivalent booster","volume":"388","author":"Jabagi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101630_bib18","doi-asserted-by":"crossref","first-page":"e2094","DOI":"10.1212\/WNL.0000000000207847","article-title":"Risk of Guillain-Barr\u00e9 syndrome following COVID-19 vaccines: a nationwide self-controlled case series study","volume":"101","author":"Le Vu","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.lanepe.2026.101630_bib19","doi-asserted-by":"crossref","first-page":"7745","DOI":"10.1038\/s41467-024-52038-6","article-title":"Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis","volume":"15","author":"Le Vu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanepe.2026.101630_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"18","author":"Vandenbroucke","year":"2007","journal-title":"Epidemiol Camb Mass"},{"key":"10.1016\/j.lanepe.2026.101630_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020","volume":"41","author":"Moll","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101630_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2288-11-49","article-title":"Methodological challenges when estimating the effects of season and seasonal exposures on birth outcomes","volume":"11","author":"Strand","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.lanepe.2026.101630_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","article-title":"A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)","volume":"131","author":"Ulm","year":"1990","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101630_bib25","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.vaccine.2023.09.039","article-title":"The Brighton collaboration standardized module for vaccine benefit-risk assessment","volume":"42","author":"Levitan","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101630_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.3918","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.lanepe.2026.101630_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/SLA.0000000000000780","article-title":"Risk of acute appendicitis in and around pregnancy: a population-based cohort study from England","volume":"261","author":"Zingone","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.lanepe.2026.101630_bib28","article-title":"Incidence of facial nerve palsy in pregnancy","volume":"14","author":"Bose","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.lanepe.2026.101630_bib29","article-title":"Gestational thrombocytopenia: a review on recent updates","volume":"14","author":"Habas","year":"2022","journal-title":"Cureus"},{"issue":"Suppl 1","key":"10.1016\/j.lanepe.2026.101630_bib30","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0049-3848(17)30069-5","article-title":"Disseminated intravascular coagulation in pregnancy\u2013clinical phenotypes and diagnostic scores","volume":"151","author":"Erez","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.lanepe.2026.101630_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251365626","article-title":"An analysis of incidence, related factors and prophylactic treatments of hospital-acquired upper extremity deep vein thrombosis: a single-center 13-year retrospective study","volume":"31","author":"Wang","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.lanepe.2026.101630_bib32","series-title":"Briefing document Pfizer-BioNTech COVID-19 Vaccine","year":"2020"},{"key":"10.1016\/j.lanepe.2026.101630_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2021.100122","article-title":"Appendicitis as a possible safety signal for the COVID-19 vaccines","volume":"9","author":"Mitchell","year":"2021","journal-title":"Vaccine X"},{"key":"10.1016\/j.lanepe.2026.101630_bib34","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101630_bib35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamainternmed.2022.1222","article-title":"Risk of appendicitis after mRNA COVID-19 vaccination in a Danish population","volume":"182","author":"Kildegaard","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lanepe.2026.101630_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40264-024-01422-8","article-title":"Lessons learned on observed-to-expected analysis using spontaneous reports during mass vaccination","volume":"47","author":"Gordillo-Mara\u00f1\u00f3n","year":"2024","journal-title":"Drug Saf"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:20:38Z","timestamp":1778923238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"alternative-id":["S2666776226000426"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101630","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background incidence rates and observed-to-expected ratios of adverse events of special interest after covid-19 mRNA vaccination during pregnancy in France: a nationwide population-based study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101630"}}